Article and Video CATEGORIES

Cancer Journey

Search By

 Dr. Kurian is a medical oncologist at St. Elizabeth Yung Family Cancer Center and is an assistant professor of medicine at the University of Kentucky College of Medicine. He completed his oncology fellowship at NCI designated University Hospitals/Case Comprehensive Cancer Center and served as the 2022-2023 Chief Fellow of the Hematology/Oncology Fellowship Program. His main focus is in breast and genitourinary cancers. His interests include ctDNA, narrative medicine, medical education, clinical trial access in the community, and artificial intelligence. At St.

Program: Patient Education Ambassadors 2023-24
AlexandraGBeneke
The 2023-2024 GRACE Patient Education Ambassadors discuss topics in a variety of cancers, from screening and treating prostate cancer to aiding in the cost of cancer treatment.
Author
Matthew Kurian, MD - Guest Faculty
Image
Patient Education Ambassadors 2023-24

Drs. Matthew Kurian, Karan Jatwani, and Karine Tawagi discuss risk factors for developing prostate cancer, PSA test in prostate cancer screening, biopsies in prostate cancer, among other relevant information about prostate cancer.

To watch the full playlist click here.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on